Skip to main content
رجوع
PGEN logo

Precigen, Inc.

جودة البيانات: 100%
PGEN
NASDAQ Healthcare Biotechnology
KWD 3.10
▼ KWD 0.03 (-0.96%)
القيمة السوقية: 931.33M
نطاق اليوم
KWD 3.04 KWD 3.25
نطاق 52 أسبوعًا
KWD 1.11 KWD 5.47
حجم التداول
5,959,675
متوسط 50 يوم / 200 يوم
KWD 4.17 / KWD 3.40
الإغلاق السابق
KWD 3.13

Quick Summary

تاريخ السعر

الاتجاهات المالية

مقارنة الأقران

مقابل وسيط قطاع Healthcare (631 نظير)

المقياس السهم وسيط القطاع
P/E -2.2 0.2
P/B 44.5 3.0
ROE % -1446.0 3.6
Net Margin % -4436.6 3.8
Rev Growth 5Y % -9.2 9.9
D/E 4.7 0.2

السعر المستهدف للمحللين

Hold
KWD 6.00 +93.5%
ربحية السهم المستقبلية
-KWD 0.18
الإيرادات المقدّرة
98.61M

تقديرات الأرباح

الفترة تقدير ربحية السهم تقدير الإيرادات المحللون
FY2029 KWD 0.63
KWD 0.49 – KWD 0.77
451.33M 1
FY2028 KWD 0.38
KWD 0.30 – KWD 0.47
331.11M 1
FY2027 KWD 0.07
-KWD 0.01 – KWD 0.16
205.37M 2

Earnings Surprises

Last 8 quarters
Quarter Est. EPS Actual EPS Surprise
2026-03-25 -KWD 0.08 -KWD 0.08 -0.1%
2025-11-13 -KWD 0.08 -KWD 0.11 -37.5%
2025-08-12 -KWD 0.14 -KWD 0.11 +21.4%
2025-05-14 -KWD 0.08 -KWD 0.07 +12.5%
2025-03-19 -KWD 0.06 -KWD 0.04 +33.3%
2024-11-14 -KWD 0.08 -KWD 0.09 -12.5%
2024-08-14 -KWD 0.09 -KWD 0.10 -11.1%
2024-05-14 -KWD 0.09 -KWD 0.10 -11.1%

Dividend History

Yield

0.00%

Payout Ratio

0.00%

Growth (3Y)

N/A

Growth (5Y)

N/A

No dividend history available.

النقاط الرئيسية

Revenue declined -9.23% annually over 5 years
Debt/Equity of 4.70 — high leverage
Negative free cash flow of -87.83M
Revenue growth is accelerating — 1Y growth exceeds 5Y average by 155.96%
Capital efficient — spends only 0.00% of revenue on capex
ROIC of 0.00% — low return on invested capital

النمو

Revenue Growth (5Y)
-9.23%
Revenue (1Y)146.73%
Earnings (1Y)N/A
FCF Growth (3Y)N/A

الجودة

Return on Equity
-1446.02%
ROIC0.00%
Net Margin-4436.62%
Op. Margin0.00%

الأمان

Debt / Equity
4.70
Current Ratio3.09
Interest Coverage0.00

التقييم

P/E Ratio
-2.17
Forward P/EN/A
P/B Ratio44.54
EV/EBITDAN/A
Dividend Yield0.00%

All Fundamental Metrics

Growth
Revenue Growth (1Y) 146.73% Revenue Growth (3Y) 24.73%
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) -9.23% Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 9.68M Net Income (TTM) -429.64M
ROE -1446.02% ROA -276.29%
Gross Margin 0.00% Operating Margin 0.00%
Net Margin -4436.62% Free Cash Flow (TTM) -87.83M
ROIC 0.00% FCF Growth (3Y) N/A
Safety
Debt / Equity 4.70 Current Ratio 3.09
Interest Coverage 0.00
Dividends
Dividend Yield 0.00% Payout Ratio 0.00%
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A
Valuation
P/E Ratio -2.17 Forward P/E N/A
P/B Ratio 44.54 P/S Ratio 96.17
PEG Ratio 0.00 Forward PEG N/A
EV/EBITDA N/A Fwd EV/EBITDA N/A
Forward P/S 9.44 Fwd Earnings Yield N/A
FCF Yield -9.43%
Market Cap 931.33M Enterprise Value 999.38M

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 9.68M 3.93M 6.23M 26.91M 14.27M
Net Income -429.64M -126.24M -95.90M 28.32M -92.17M
EPS (Diluted) -1.37 -0.47 -0.39 -0.33 -0.47
Gross Profit 0.0 -342,000.0 106,000.0 20.57M -39.41M
Operating Income 0.0 -135.03M -99.76M -75.73M -91.95M

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 155.51M 145.27M 151.04M 215.98M 359.86M
Total Liabilities 134.59M 106.75M 32.55M 89.72M 252.51M
Shareholders' Equity 20.91M 38.51M 118.50M 126.26M 107.35M
Total Debt 98.29M 5.50M 7.10M 51.42M 190.07M
Cash & Equivalents 30.23M 29.52M 7.58M 4.86M 36.42M
Current Assets 115.24M 102.41M 68.76M 118.16M 156.63M
Current Liabilities 37.31M 21.52M 22.99M 78.65M 34.65M